about
Depressogenic effects of medications: a reviewL-asparaginase in the treatment of patients with acute lymphoblastic leukemiaDevelopment of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemiaHLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Intestinal and liver toxicity of antineoplastic drugs.Pulmonary toxicity of antineoplastic agentsImmunological responses to L-asparaginase.Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity.Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.Parathyroid necrosis and hypocalcemic tetany induced in rabbits by L-asparaginase.Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase.Tumor inhibitory and non-tumor inhibitory L-asparaginases from Pseudomonas geniculata.Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012.Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).High-throughput asparaginase activity assay in serum of children with leukemiaPrevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.L-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia.Erwinia asparaginase in pediatric acute lymphoblastic leukemia.L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia.Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.The influence of the iso-electric point of L-asparaginase upon its persistence in the bloodSuccessful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma.Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors.Cloning and characterization of Halomonas elongata L-asparaginase, a promising chemotherapeutic agent.Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial.Central nervous system prophylaxis with high-dose methotrexate does not give rise to significant electroencephalographic changes in children with acute lymphoblastic leukemia.Beta-aspartylpeptides as substrates of L-asparaginases from Escherichia coli and Erwinia chrysanthemi.On the origin of EEG-slowing and encephalopathy during induction treatment of acute lymphoblastic leukemia.Liver histology after current intensified therapy for childhood acute lymphoblastic leukemia: microvesicular fatty change and siderosis are the main findings.Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.Acute encephalopathy during induction therapy for acute lymphoblastic leukemia.l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?Expression of CD203c on basophils as a marker of immunoglobulin E-mediated (L)-asparaginase allergy.Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
P2860
Q24635465-0744BE84-9700-4ABF-A87D-36E85661CE4EQ26738640-EA0DCE12-3D9B-4380-AA5D-4DE4539CFF33Q26825970-B87E8B65-E2D0-49FF-9803-CCD107D6DADFQ30371340-D429EBD5-2ADD-4599-8BEF-85A63C9B46ABQ33605823-D0A7E139-5C07-4DCB-AEB4-1CA413E715A9Q34051251-3328597E-96A8-46EE-A2EA-4639C6363FECQ34060926-A91BF1BF-511F-472F-B146-1D9DFCFCFE6DQ34400003-CDA8ABF4-A459-40A8-8948-D7130A991AFFQ34571555-3B9E7B7F-B3F8-416A-A2E4-7593D1C40306Q35025684-6DE2466E-4505-4374-A820-6E1390314361Q36078687-E0F6C807-9E91-4FB6-A6D5-367FE77AAA34Q36284750-9D4EF877-D3BE-459F-864E-759CA63D8408Q36340500-B45F41A1-8C79-4969-B7F1-33F8E8F09697Q36452241-BC960949-2DB3-4698-B327-553020BD7028Q36463010-BC7D8A40-F3E5-4002-93CA-CAE9CD261891Q36570330-7BDF8E67-CF28-466E-B6B2-70C3BFDC583FQ37063860-41F69B91-2329-4964-BD61-6D116BD817C1Q37914185-D95EB89E-CC8C-4271-9118-C5678BA8F805Q38017602-7012CA6A-03C1-408D-BBBE-05D7422C1615Q38040418-FE27EE8D-D875-4F87-8BFA-F1DB84FEE46CQ38105626-711581BC-F65B-4710-8D1F-7A38C49BDAD1Q38248280-CB58C674-725E-4A2D-BB58-058A3A8E863DQ38696311-50FDDE7B-6E48-4A7C-AAC2-69E162439A4BQ39947317-95E5D15C-2150-4027-946B-32FA47918EFDQ40557017-24103E97-32AA-423E-ACE4-2B6BA5A75EE1Q41021920-C6BB2364-BE9C-4CCF-AF1E-51A72B8961FDQ41554076-049B2A80-48B1-42F8-B595-4C4FE840A180Q43031862-F485AE26-DC4D-47BB-B08C-E8C67E643EEFQ44033587-416FAD58-0166-4DBD-9477-A3C7AF166725Q44099479-DFA5A661-C1AD-44F7-9B7E-325FF5D67D41Q44151227-370EAFDF-2366-410F-8111-541C79D9E197Q44177466-B7AE98B6-68E4-48CF-AC5E-A1EC63B996F6Q44272409-DA548E86-D0C6-4E99-9971-6EAF76BB19F9Q44824850-61C559EF-3173-4A65-BFA6-E56205765B9DQ48410622-641B5C14-7122-4D6C-8170-899C3D75D34CQ50545214-70ED0CC3-1DB6-4A00-922E-92CECB6BBFE9Q50602508-86B08837-62D6-47F9-818E-A5739134EAE6Q51071633-1B9CA7D3-A935-45A9-93DE-48821990CED3Q51762163-CC630F30-BA68-4DFF-85A2-324808BED402Q53713010-9597BF20-4E70-4688-B6DB-E05CA2D2BBD8
P2860
description
1970 nî lūn-bûn
@nan
1970年の論文
@ja
1970年論文
@yue
1970年論文
@zh-hant
1970年論文
@zh-hk
1970年論文
@zh-mo
1970年論文
@zh-tw
1970年论文
@wuu
1970年论文
@zh
1970年论文
@zh-cn
name
Toxicity of E. coli L-asparaginase in man.
@en
type
label
Toxicity of E. coli L-asparaginase in man.
@en
prefLabel
Toxicity of E. coli L-asparaginase in man.
@en
P2093
P1433
P1476
Toxicity of E. coli L-asparaginase in man.
@en
P2093
B D Clarkson
D A Karnofsky
H F Oettgen
I H Krakoff
J H Burchenal
M K Schwartz
M L Murphy
P A Stephenson
P304
P356
10.1002/1097-0142(197002)25:2<253::AID-CNCR2820250204>3.0.CO;2-U
P407
P577
1970-02-01T00:00:00Z